[1] Steinman S, Wang J, Bourne P, Yang Q, Tang P. [J]. Annals of Clinical and Laboratory Science: Official Journal of the Association of Clinical Scientists 2007. [2] TANAKA K, IWAMOTO S, GON G. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas [J]. Clinical Cancer Research 2000, 6(01). [3] 詹启敏. 分子肿瘤学 [M]. 北京:人民卫生出版社 2005. [4] Montagna Cristina, Andrechek EranR, Padilla-Nash Hesed, Muller WilliamJ, Ried Thomas. Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu. [J]. Oncogene 2002, 6(6). [5] Vollmann-Zwerenz, A, Diermeier-Daucher, S, Wege, AK, Sassen, A, Schmidt-Brucken, E, Hofstaedter, F, Ortmann, O, Nauwelaers, F, Brockhoff, G. [J]. Cytometry, Part A: the journal of the International Society for Analytical Cytology 2010. [6] DENHOIT C L, BINDERUP T, STOCKHAUSEN M T. Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a position emission tomography tracer for epidermal growth factor receptor mutation variant Ⅲ imaging in cancer [J]. Nucl Med Bid 2011, 38(04). |